Evommune and Nektar released clinical data showing prolonged and meaningful skin improvements in patients with moderate-to-severe atopic dermatitis. Evommune reported that EVO301, an IL-18–binding fusion, achieved statistically significant EASI reductions in a Phase 2a placebo-controlled study. Nektar disclosed one-year maintenance data for rezpegaldesleukin, showing large proportions of responders retained or deepened EASI-75 responses after switching to longer-interval dosing. Both companies positioned the results as evidence their mechanisms could offer competitive alternatives to incumbent IL‑4/IL‑13 blockade. Evommune is planning a subcutaneous Phase 2b to optimize dosing; Nektar intends a Phase 3 program with responder-maintenance designs. Eczema Area and Severity Index (EASI) is a validated clinician-scored scale for skin lesion extent and severity used as a primary endpoint in dermatitis trials. For clinicians and payers, the data suggest potential efficacy with less-frequent dosing or differentiated mechanisms. Investors reacted strongly to the toplines, reflecting market appetite for therapies that address the ~40% of patients with inadequately controlled disease.